Snowflake (NYSE: SNOW), the AI Data Cloud company, today announced advancements that make data AI-ready by design, allowing ...

Leading enterprises including BlueCloud and Sigma Computing will rely on Snowflake Postgres to reduce data silos and complex data pipelines for AI and analytics use cases Snowflake Horizon ...

Researchers using China’s “artificial sun” fusion reactor have broken through a long-standing density barrier in fusion plasma. The experiment confirmed that plasma can remain stable even at extreme ...

This repository contains comprehensive research, learning materials, and implementation scripts for deploying Microsoft Power BI across your organization, with specific focus on PostgreSQL database ...

As the science of Crohn’s disease (CD) rapidly evolves, the American Gastroenterological Association (AGA) has issued a living guideline on the pharmacologic management of moderately to severely ...

Just eight months after Gemini 2.5 launched, Google has upgraded its AI models once again with the release of Gemini 3. Gemini 3 officially began rolling out widely on November 18, and even this early ...

Trump wants Nvidia's advanced Blackwell chips for US companies only Nvidia has said it would supply Blackwell chips to South Korea Trump had hinted at scaled-down Blackwell chip sales to China in ...

MSNBC's Rachel Maddow warns that the government today has access to technology that previous authoritarian regimes couldn't have dreamed of, discussing a spyware program called Pegasus, which allows ...

Chris is a writer and editor with over 10 years of experience covering games and has a bachelor's degree in History from the University of Central Lancashire. He's mainly focused on guides, but has ...

Whether it's a job or being with friends, big words aren't always meant to be used in everyday conversation. Even if smart people can throw in complex words to show off their intellect, it's not ...

Cemiplimab plus chemotherapy doubled the 5-year survival rate compared to chemotherapy alone in advanced NSCLC patients. The EMPOWER-Lung 3 trial showed a median overall survival of 21.1 months with ...